WO2006124544A3 - Use of tyrosine kinase inhibitors in the treatment of metabolic disorders - Google Patents
Use of tyrosine kinase inhibitors in the treatment of metabolic disorders Download PDFInfo
- Publication number
- WO2006124544A3 WO2006124544A3 PCT/US2006/018342 US2006018342W WO2006124544A3 WO 2006124544 A3 WO2006124544 A3 WO 2006124544A3 US 2006018342 W US2006018342 W US 2006018342W WO 2006124544 A3 WO2006124544 A3 WO 2006124544A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- treatment
- metabolic disorders
- adipocyte
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
The present invention relates to the use of c-Abl-, PDGF-R-, c-kit-, or ARG-tyrosine kinase inhibitors, or pharmaceutically acceptable salts thereof, for the treatment, amelioration, and diagnosis of disorders associated with aberrant expression of adipocyte-specific peptide hormone in a patient, e.g., metabolic disorders, e.g., type I diabetes or type II diabetes, and for the manufacture of pharmaceutical compositions for the treatment, amelioration, and diagnosis of disorders associated with aberrant expression of adipocyte-specific peptide hormone in a patient. Examples of c-Abl-, PDGF-R-, c-kit-, or ARG-tyrosine kinase inhibitors include Compound I and Compound II, and pharmaceutically acceptable salts thereof. The ability of the c-Abl-, PDGF-R-, c-kit-, or ARG-tyrosine kinase inhibitors, or pharmaceutically acceptable salts thereof, to treat metabolic disorders is based at least in part on their ability to bind adipocyte-specific peptide hormones such as adiponectin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68071405P | 2005-05-13 | 2005-05-13 | |
US60/680,714 | 2005-05-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006124544A2 WO2006124544A2 (en) | 2006-11-23 |
WO2006124544A3 true WO2006124544A3 (en) | 2007-09-07 |
Family
ID=37431881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/018342 WO2006124544A2 (en) | 2005-05-13 | 2006-05-11 | Use of tyrosine kinase inhibitors in the treatment of metabolic disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006124544A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102812011A (en) | 2009-11-16 | 2012-12-05 | 梅利科技公司 | [1,5]-diazocin Derivatives |
IL234962A0 (en) * | 2014-10-02 | 2015-01-29 | Yeda Res & Dev | Use of agents for treating fat-related disorders |
CN116173023A (en) * | 2022-09-09 | 2023-05-30 | 中南民族大学 | New application of lenvatinib in preventing and treating type II diabetes |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009367A2 (en) * | 2003-07-17 | 2005-02-03 | Ambit Biosciences Corporation | Treatment of diseases with kinase inhibitors |
-
2006
- 2006-05-11 WO PCT/US2006/018342 patent/WO2006124544A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009367A2 (en) * | 2003-07-17 | 2005-02-03 | Ambit Biosciences Corporation | Treatment of diseases with kinase inhibitors |
Non-Patent Citations (1)
Title |
---|
LASSILA M ET AL: "IMATINIB ATTENUATES DIABETES-ASSOCIATED ATHEROSCLEROSIS", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 24, no. 5, May 2004 (2004-05-01), pages 935 - 942, XP008037837, ISSN: 1079-5642 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006124544A2 (en) | 2006-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005072045A3 (en) | The combined use of glp-1 agonists and gastrin for regulating blood glucose levels | |
WO2006037031A3 (en) | Formulations and methods for treatment of inflammatory diseases | |
WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
WO2007087068A3 (en) | Inhibitors of tyrosine kinases and uses thereof | |
EA200800007A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON NEUROACTIVE STEROID AND THEIR APPLICATION | |
WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
WO2005070462A3 (en) | Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use | |
WO2006034373A8 (en) | Variants and chemically-modified variants of phenylalanine ammonia-lyase | |
WO2010009892A3 (en) | Compositions for the treatment of pain and/or inflamation | |
WO2006055708A3 (en) | Heterocycle substituted carboxylic acids for the treatment of diabetes | |
WO2007093450A3 (en) | Deuterated catecholamine derivatives and medicaments comprising said compounds | |
TN2009000095A1 (en) | Thiazole pyrazolopyrimidines as crf1 receptor antagonists | |
MXPA05007857A (en) | Indole-derivative modulators of steroid hormone nuclear receptors. | |
WO2009127974A3 (en) | Pharmaceutical formulation for treating cardiovascular disease | |
WO2004099168A3 (en) | Substituted carboxylic acids | |
NO20073774L (en) | Therapeutic compounds for intranasal administration of ketorolac | |
WO2004017896A3 (en) | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist | |
EP3276004A3 (en) | Methods for treating chronic kidney disease | |
WO2008062446A3 (en) | An extended release composition of levetiracetam, which exhibits no adverse food effect | |
MY147391A (en) | Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds | |
WO2008030830A3 (en) | Sustained-release composition and method of use thereof | |
WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
WO2006124544A3 (en) | Use of tyrosine kinase inhibitors in the treatment of metabolic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06759626 Country of ref document: EP Kind code of ref document: A2 |